A Clinical Trial of Telehealth Treatment for Opioid Use Disorders
ConditionOpioid Use Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorYale University
About this trial
This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Can speak, read and write in English
Provision of signed and dated informed consent form
Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer)
Disqualifiers
Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
Pregnancy
Known current suicide risk based on participant self-report
On parole or incarcerated at time of enrollment based on participant self-report
Trial design
Design model
Parallel
Treatments tested in this trial
RecoveryPad platform
DeviceTelehealth platform to enhance motivation and engagement in treatment for OUD
Treatment groups
470 Participants
are divided into 2 treatment groupsGroup A: RecoveryPad platformExperimental treatment 1 intervention
Group B: Treatment as usualNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Attendance for MOUD
Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 30 days of enrollment.
Time frame
Up to 30 daysSecondary outcomes
1
Attendance for MOUD
Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 31 to 90 days of enrollment.
Time frame
Up to 90 days2
Engagement with MOUD
Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of enrollment.
Time frame
Up to 90 days3
Overdose Events at 30 Days
A self-report of the number of subsequent overdose events within 30 days.
Time frame
Up to 30 days4
Overdose Events at 90 Days
A self-report of the number of subsequent overdose events within 90 days.
Time frame
Up to 90 daysSponsors and contacts
Click on the lead sponsor to view all of their trials.
Yale University
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
City University of New York, School of Public Health
Collaborator
Source ClinicalTrials.gov